Clinical TrialJun 4, 2026, 08:01 AM
Immutep's IMP761 Phase I met primary endpoint, showed significant activity
AI Summary
Immutep announced positive first-in-human Phase I clinical data for its lead autoimmune candidate, IMP761, presented at the EULAR Congress. The study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers. IMP761 showed statistically significant pharmacodynamic activity at 7 mg/kg, including reduced inflammatory responses and attenuated T-cell activity, supporting further clinical investigation in autoimmune diseases.
Key Highlights
- Immutep's IMP761 Phase I study met its primary endpoint for safety and tolerability.
- Statistically significant pharmacodynamic activity observed at 7 mg/kg dose.
- Skin blood perfusion at 7 mg/kg was statistically better than placebo (p = 0.029).
- IMP761 was safe and well tolerated across all tested dose levels.
- Pharmacokinetics support once per 4-week dosing for IMP761.
- Further clinical investigation in autoimmune diseases is supported.
- Additional trial updates for IMP761 expected in H2 CY2026.
Price Impact
More from IMMP
More in Clinical Trial